key: cord-0973006-3mwv35rw authors: Horlacher, Marc; Oleshko, Svitlana; Hu, Yue; Ghanbari, Mahsa; Cantini, Giulia; Schinke, Patrick; Vergara, Ernesto Elorduy; Bittner, Florian; Mueller, Nikola S.; Ohler, Uwe; Moyon, Lambert; Marsico, Annalisa title: Computational Mapping of the Human-SARS-CoV-2 Protein-RNA Interactome date: 2022-05-04 journal: bioRxiv DOI: 10.1101/2021.12.22.472458 sha: 718e85aa1fcc41501e36913a6658ac07aa3b41db doc_id: 973006 cord_uid: 3mwv35rw Strong evidence suggests that human human RNA-binding proteins (RBPs) are critical factors for viral infection, yet there is no feasible experimental approach to map exact binding sites of RBPs across the SARS-CoV-2 genome systematically at a large scale. We investigated the role of RBPs in the context of SARS-CoV-2 by constructing the first in silico map of human RBP / viral RNA interactions at nucleotide-resolution using two deep learning methods (pysster and DeepRiPe) trained on data from CLIP-seq experiments. We evaluated conservation of RBP binding between 6 other human pathogenic coronaviruses and identified sites of conserved and differential binding in the UTRs of SARS-CoV-1, SARS-CoV-2 and MERS. We scored the impact of variants from 11 viral strains on protein-RNA interaction, identifying a set of gain-and loss of binding events. Lastly, we linked RBPs to functional data and OMICs from other studies, and identified MBNL1, FTO and FXR2 as potential clinical biomarkers. Our results contribute towards a deeper understanding of how viruses hijack host cellular pathways and are available through a comprehensive online resource (https://sc2rbpmap.helmholtz-muenchen.de). and 3b each show single-nucleotide resolution prediction scores of the well-known human RBPs RBFOX2 155 and TARDBP, obtained from pysster models, and MBNL1 and QKI, obtained from DeepRiPe models. Identified 156 binding sites (Methods 3.9) are shown below the prediction score tracks. To identify driving features of RBP binding predicted binding of RBPs, in order to uncover potential viral hijacking of host proteins directly at the RNA level. A catalog of high-impacting variants across 11 viral strains 265 We compiled a total of 290 mutations (193 unique mutations, 37 shared across strains) across 11 variants of concern, 266 including alpha, delta, and omicron strains (Methods 3.11). For each variant and RBP, we evaluated the impact of 267 the variant in terms of gain-or loss-of-binding by comparing the predicted binding probability of the reference and 268 alternative allele (Methods 3.11.) Using pysster and DeepRiPe models across 87 RBPs, we obtained a total of 25,230 269 impact scores, one for each pair of variant and RBP. Notably, three variants (3, 037C>T, 14,408C>T, and 23,403A>G) 270 are consistently found across all viral strains, and their highest absolute delta-scores were respectively associated to 271 FTO (avg. decrease from 0.474 to 0.356), AQR (avg. decrease from 0.191 to 0.036), and NONO (avg. increase from 272 0.086 to 0.340). In order to prioritize pairs of variants and RBPs that show a gain-or loss-of-binding, we select a 273 sub-set of pairs for which either the reference or alternative allele pass our binding thresholds (Methods 3.9). Note that 274 this filter applies a XOR operation, i.e. we are interested in events that lead to either gain-or loss-of-binding (GOB, 275 LOB). Overall, a total of 315 GOB or LOB events passed the above filter and are depicted in Figure 4a . The majority 276 of variants introduced small delta in prediction scores, with less than 20% (61) impact scores is available at https://sc2rbpmap.helmholtz-muenchen.de/. 295 High-impact sequence variants disrupt known RBP-binding motifs 296 As in vivo RBP-binding is usually driven via the recognition of short sequence motifs, we investigated whether 297 high-impact variants cause gain or disruption of known binding motifs. To this end, we gathered from each strain 298 the top 10 variants with highest absolute delta-scores, as illustrated in Figure 4b and 4c for strains alpha and delta, 299 respectively. This represented a total of 69 unique mutation-RBP pairs, 19 of which were found in more than one 300 strain. As expected, the majority (54 / 69) of their delta-scores is found to be in the top 1% of the distributions from the 301 in silico mutagenesis. We then computed feature attribution scores (Methods 3.10), centered at the position of each 302 high-impact variant. Feature attribution maps for the subset of candidate high-impact variants of the alpha and delta 303 strain are shown in Figure 4b and 4c, respectively. Indeed, we observe that variants with high negative delta score 304 tend to disrupt known binding motifs of human RBPs. For instance, transition T>G at position 22,917, as seen in the 305 delta strain (Figure 4c ) (as well as in top mutations from epsilon and kappa strains) decreases the prediction score for 306 PUM2 from 0.795 to 0.158, with only 0.0015% in silico variants showing a lower delta-score. As is clearly visible 307 from the feature attribution analysis (Figure 4c ; middle-right), the variant disrupts the well-known PUM2 binding motif 308 TGTATAT. In a similar manner, transversion A>T at position 23,063 from the alpha strain (Figure 4b ; also found in top 309 mutations from beta, gamma, and mu strains) decreases the prediction score for QKI from 0.488 to 0.049, with 0.006% 310 in silico mutations show a low delta-score. Here, the feature attribution profiles clearly highlight how the known QKI 311 binding motif ACTAA was detected by the model in the reference sequence, and how the mutation leads to a loss of 312 this motif. Lastly, the transversion G>C at position 28,280 in the alpha strain ( Figure 4b ) decreases the prediction score 313 for FTO binding from 0.679 to 0.209, and only 6 (0.00007%) in silico mutations show a delta-score lower than the one observed ( Figure 4d ). Although no clear motif is found within the window, the heights of the nucleotides at the position 315 of the mutation are reduced compared to the reference sequence, reflecting the decreased prediction score. 316 Among the above set of top 10 highest impact variants per viral strain, we select those that conform to strict gain-or 318 loss-of-binding (Methods 3.11). We identify a total of 23 (out of 69) change of binding events across 17 variants and 319 13 RBPs (Table 1 ). The first example corresponds to a transversion G>T at position 210 in the 5'UTR from the delta 320 and kappa strains, predicted to induce a loss-of-binding for SRSF7, which we had confirmed from the loss of binding 321 motif (delta strain heatmap, see Figure 4c ). Further, from the ORF1ab gene, two examples of a loss of binding for 322 RBM20 by the C>T transition at position 3,267 (strain alpha), and a gain of binding of RBM22 from a C>T transition at 323 position 18,877 (strain mu). From the S gene, a gain of binding is reported for HNRNPC, induced by a C>T transition 324 at position 21,575 (strain iota), in addition to another gain of binding reported for SF3A3, from a C>A transversion 325 at position 22,995 (strain omicron). Two mutations occurring in the ORF3a gene are passing our filters for two RBP 326 impacts: the transition C>T at position 25,469 induces a gain of binding for HNRNPC in delta and kappa strains, while 327 the G>T transversion at position 25,563 induces a loss of binding for FTO in strains beta, epsilon, iota and mu. Finally, 328 in the N gene, we report three mutations, two of them impacting FTO binding (one gain in the eta strain, from a deletion 329 at position 28,278; one loss in the alpha strain, from a G>C transversion at position 28,280), and a loss of binding of 330 ORF1 protein (from LINE-1 retrotransposable element) in the eta strain, from a A>G transversion at position 28,699. Individual variants impact binding of several RBPs 332 Among variants that surpass binding-sites thresholds and lead to either gain-or loss-of-binding (Methods 3.11), several 333 variants impact RBP binding of multiple RBPs simultaneously. For instance, a deletion at position 22,299 (S gene) 334 identified in the lambda strain, is predicted to induce a gain of binding for ELAVL1, U2AF2, and GPKOW, while 335 inducing a loss of binding for SF3B4, SF3A3, and MBNL1. Interestingly, all these factors are associated with splicing. Notably, the MBNL1 loss is also detected in the beta strain, through a deletion happening in a close-by location (at 337 position 22,281, S gene), suggesting those two mutations may have been retained due to beneficial induction of similar 338 changes in binding patterns. Another mutation which impacts multiple RBPs is the transition G>A at position 23,048 (S 339 gene) from the omicron strain, predicted to induce binding of the ORF1 protein from LINE-1 retrotransposable element, 340 as well as of SND1. Comparably to the MBNL1 impact, two close-by mutations from omicron were associated with a 341 gain of ORF1 binding (transversion A>C at position 23,013, and transition A>G at position 23,040), further suggesting 342 joint impact of these mutations on ORF1p binding. The last case of mutations with impact on multiple RBPs concerns a 343 set of 2 mutations: C>A transversion and C>G transversion at position 23,604, in the S gene. The first is found in alpha 344 and mu strains, while the second is found in the delta and kappa strains. Both mutations are predicted to induce a gain 345 of SRSF7 binding, which is visualized for the alpha strain on Figure 4b through feature attribution maps. HCoV-OC43, HCoV-NL63, HCoV-HKU1, HCoV-229E (Methods 3.13). Binding sites were identified in analogy to 353 SARS-CoV-2 (Methods 3.9) across each viral genome using 87 high-confidence pysster and DeepRiPe models. Figure 354 5a shows the general binding propensity of RBPs across viral genomes of the 7 coronaviruses. Overall, RBP binding is 355 conserved across coronaviruses, with the highly pathogenic viruses (SARS-CoV-1, SARS-CoV-2 and MERS) showing 356 a highly similar binding pattern. Further, a total of 86 (out of 87) RBPs (except FKBP4) were predicted to harbor a 357 binding site in at least one coronavirus, with only a small variability in the total number of binding RBPs between 358 individual viruses. However, we observe a greater variability of RBP binding within shared genomic regions across 359 coronaviruses, for instance in the 5' and 3' untranslated regions (UTRs). Viral UTRs are known to play an important 360 role in both pro-and anti-viral responses and recent evidence suggests that evolution of the 3' UTR is contributing 361 to increased viral diversity (15). Indeed, the 3' UTR of SARS-CoV-2 shows a severe truncation when compared to 362 SARS-CoV-1 and MERS. Given that viral UTRs are not under selective pressure with respect to a translated protein, 363 they might be more prone to acquire mutations that modulate regulation through host RBPs. Figure 5b and 5c show 364 RBP binding to the 3' and 5' UTRs across selected coronaviruses, respectively. While SARS-CoV-1, SARS-CoV-2 365 and MERS show conserved binding on the 5' UTR and cluster closely, a depletion of RBP binding sites is observed in 366 the 3' UTR of SARS-CoV-2 when compared to SARS-CoV-1 and MERS. To investigate gain-and loss-of-binding in 367 viral UTRs across the severe pathogenic human coronaviruses SARS-CoV-1, SARS-CoV-2 and MERS, we performed 368 multiple sequence alignment of the viral 3' and 5' UTRs and compared the predicted binding score profiles across the 369 three viruses (Methods 3.13). Figure 5e shows 3' UTR binding of FXR2, a paralog of FMRP (fragile X mental retardation protein). Our model 372 predicted extensive binding of FXR2 along the 3' UTR of SARS-CoV-1 and MERS, while SARS-CoV-2 showed a 373 complete lack of predicted FXR2 binding sites, owing to its significantly shorter 3' UTR. On the other hand, Figure 5g 374 shows that FXR2 binding is conserved in the 5' UTR of SARS-CoV-1 and SARS-CoV-2. FMRP was previously shown 375 to broadly bind along the entirety the 3' UTR of the Zika virus (ZIKV) (74). However, while FMRP was suggested to 376 act as a ZIKV restriction factor by blocking viral RNA translation, a significantly reduced ZIKV infection was observed 377 upon knockdown of FXR2 (74). Conserved FTO binding site in the 3' UTR of SARS-CoV-1 and SARS-CoV-2 379 Altered expression levels of methyltransferase-like 3 (METTL3) and fat mass and obesity-associated protein (FTO) 380 have been recently linked to viral replication (99). FTO is a demethylase (eraser) enzyme with enriched binding in the 381 3' UTR of mRNAs in mammals (58). FTO has previously been suggested as a potential drug target against COVID-19 382 (97), as targeted knockdown has been shown to significantly decrease SARS-CoV-2 infection (99; 97; 6). Therefore, we 383 investigated predicted binding of FTO to the 3' UTR of SARS-CoV-2 and related viruses. Indeed, we observed that 384 SARS-CoV-1, SARS-CoV-2 and MERS, as well as the less pathogenic viruses HCoV-HKU1 and HCoV-OC43 harbor 385 at least one FTO binding site in their 3' UTR ( Figure 5b) . Further, Figure 5d shows that while SARS-CoV-1 and MERS 386 harbor multiple shared FTO binding sites along their 5' UTR, SARS-CoV-2 only harbors one FTO binding site at the 3' 387 end of its 5' UTR which is exclusively shared with SARS-CoV-1. Newly acquired TARDBP binding in the SARS-Cov-2 5' UTR 389 We next focus on TARDBP (also known as TDP-43) (Figure 5f ), which was predicted to bind the 5' UTR of a 390 SARS-CoV-2 mutant in a recent study (60). TARDBP, a host protein implicated in pre-mRNA alternative splicing, has 391 been shown to play a role in viral replication and pathogenesis in the context of coxsackievirus B3 infection (42). In to yield higher performing models (compared to K562) in previous studies (5). Narrow peaks of each eCLIP library 435 were taken directly from ENCODE and preprocessing was performed as follows: for each of the two replicates of a 436 given eCLIP experiment, peaks were first intersected with mRNA locations obtained from the GENCODE database 437 (Release 35) and only overlapping peaks were retained. Next, the 5'-end of each peak was defined as the cross-linked 438 site, as it usually corresponds to the highest accumulation of reverse transcription truncation events. A 400bp window 439 was then centered around the cross-linked site for each peak, defining the input window of the downstream model. As pysster models are trained as a 3-class classification problem with class imbalance, we re-calibrate each model for 466 the binary classification task by introducing a binary decision threshold t m on the predicted positive-class probability 467 scores. For each model m, t m is defined as the threshold which maximizes the F1 performance (Section 3.7.1) of 468 the model with respect to bound vs. unbound binary classification obtained by pooling class 2 and 3 samples into a 469 common 'unbound' class. This threshold is used to identify bound regions in the viral sequence (Section 3.9). The pysster and DeepRiPe positive-class prediction score corresponds to the probability that input RNA sequence is 482 bound by the RBP of interest. By design, this score is assigned to the entire input sequence, although RBP binding 483 sites are much more local, usually spanning only a few nucleotides (14). To obtain single-nucleotide binding site 484 probabilities from both pysster and DeepRiPe models along an RNA sequence, we employ a one-step sliding-window 485 approach to scan over a given RNA sequence, where the predicted positive-class probability score is assigned to the 486 center nucleotide of the input window. In order to obtain predictions over the entire RNA sequence, the 5' and 3' 487 sequence ends are 0-padded. As the validation loss was monitored for the purpose of early-stopping, the precision-recall (PR) and F1-score 491 performance of the pysster models was evaluated on the test set. Models with an area under the PR curve (auPRC) of 492 less than or equal to 0.6 were deemed poor quality and thus excluded from the downstream analysis. where t m is a threshold obtained for each model as outlined in Section 3.4. For each model, we perform extensive PIP 504 analysis on the human transcriptome as follows. First, we select the set of transcripts which contain at least one binding 505 site for it. From this set, we uniformly draw 100 transcripts without replacement as hold-out transcripts. Subsequently, 506 we intersect positive and negative training samples with the hold-out transcripts and discard all samples that overlap 507 with any of the hold-out transcripts before retraining pysster on the remaining training samples. We use the resulting 508 models to predict along the hold-out transcripts as described in Section 3.6 and compute the PIP score for each hold-out 509 transcript. Finally, models with a median PIP score of less than or equal to 0.1 were excluded from downstream analysis. To directly control the false positive rate of binding site prediction from both pysster and DeepRiPe models on the 512 viral genome, we estimate prediction score significance via an RNA sequence permutation test. In order to obtain a 513 null-distribution of predictions (positive-class) scores, we first compute the di-nucleotide frequencies on the viral RNA. Next, we perform frequency-weighted sampling of di-nucleotides to construct a set of N = 10, 000 null-distributed 515 inputs. Null-distributed prediction scores for each model are then obtained by predicting on those sequences. A p-value 516 is assigned to each observed prediction score p i in the viral sequence by computing the fraction of scores from the null 3.9 Identifying RBP binding sites 519 We identify RBP binding sites on the viral RNA sequence using predicted single-nucleotide binding probabilities 520 (Section 3.6) together with estimated p-values (Section 3.8). For each pysster model, we classify nucleotides in the viral 521 RNA as "bound" if the predicted probability score is equal or greater than the estimated binary threshold t m (Section 522 at least length 2 are then defined as a RBP binding site. Neighboring binding sites that are spaced by less than 10 524 nucleotides are merged to a single binding site. Note that for DeepRiPe models, nucleotides in the viral RNA are 525 considered "bound" if the probability score is found to be significant (p < 0.01) and no score threshold is applied. To gain insight into which RNA sub-sequences are driving factors for RBP binding, we compute sequence importance 528 scores using Integrated Gradients (IGs) (81; 23). Starting from an input baseline, IG performs a step-wise linear path 529 interpolation between the baseline and the actual input sequence and computes the gradients of the interpolated inputs 530 with respect to an output neuron. That is, we obtain a vector of importance scores over the input sequence which 531 indicate which nucleotides of the input contributed most toward the prediction. Here, we choose the 0-vector (i.e. the 532 one-hot encoding of all nucleotides is set to 0) as the baseline and perform 50 baseline-input interpolation steps. To 533 obtain sequence importance scores for a given binding site, we compute IGs with respect to an input window centered 534 around the binding site. For sequence-motif construction, the heights of nucleotides in the input sequence is given by 535 the feature attribution weights. Variant information of 11 SARS-CoV-2 viral variants (alpha, beta, delta, epsilon, eta, gamma, iota, kappa, lambda, 538 mu, omicron) was obtained from the UCSC genome-browser for the SARS-CoV-2 virus (17), and converted into VCF 539 format. For each strain, we first created a 'mutated' strain-specific genome, using the viral reference sequence and the 540 set of strain-defining variants. We then center a window at the reference position of each genomic variant and extract 541 the mutated sequence for subsequent prediction via each model. We note that for cases were genomic variants are 542 in close proximity with each other, extracted windows might contain multiple mutations. This is crucial, as only the 543 combination of multiple variants might lead to gain or loss of RBP binding. The resulting prediction score on each 544 alternative allele (ALT) is then compared with the prediction score of the same window on the reference sequence To quantify the impact of each mutation, we compute a delta score between the prediction score of ALT and 546 REF sequence: Mutations with a positive delta score sign represent 'gain-of-binding' (GOB) events, while mutations with negative sign is passing the binding site score threshold and p-value (Sections 3.4 and 3.8) while the ALT does not, or vice versa 551 (in case of gain of binding). As for binding site calling (Section 3.9), we use a significance level of 0.01 as p-value 552 threshold for both pysster and DeepRiPe models. Subsequently, prediction was performed on the input windows derived from each ALT allele using all high-quality 557 pysster models. Finally, as described in Section 3.11, an impact score is computed and a set of change-of-binding 558 mutations is compiled. approach generated single-nucleotide binding probabilities across the entire viral genome and may therefore yield a 620 more complete picture of the binding landscape of human RBPs to SARS-CoV-2. Our study identified known, as well as novel human RBPs to interact with SARS-CoV-2 ( Figure 6 ). Further, the and comparative analysis highlight gain-or loss-of-binding affecting host RBP-viral interactions and therefore pinpoint 643 RBPs which can be prioritized for further screening. From these two sets, we can also highlight many RBPs with functions related to endoplasmic reticulum processes. The other three sets of RBPs predicted to bind SARS-CoV-2 correspond to 1) proteins with in silico support from 711 other predictive tools, but no experimental validation of direct binding to SARS-CoV-2 (named 'Predicted only'); close-by mutations in the alpha variant that were associated to a significant loss, around the position 28,280 (Figure 4b ). Finally, the FTO protein was identified as key risk factor for obesity, which is also a known risk for COVID-19 severity. FTO coding region harbored also nominal genetic associations to COVID-19 severity (variant lowest p-value 0.0053). Interestingly, FTO was additionally found to be significantly regulated on gene level in blood serum of patients admitted 725 to ICU care (adj. p-value 7.72E-06) (63). A small set of novel predicted RBPs, with little to no experimental evidence 726 across multiple functional studies, includes the ELAVL2-4 factors, the DND1 RBP and the splicing factors SRRM4 727 and SF3A3 ( Figure 6 ). Interestingly, ELAVL2-4 RBPs, found in our analysis to be SECReTE motif-associated RBPs, 728 and SRRM4 RBP are neuron-specific proteins and were found, through our integrative analysis, to be deregulated in 729 COVID-19 patients. This points to novel promising candidates whose molecular mechanisms can be further investigated Interactions between RNA-binding proteins (RBPs) and transcripts can be experimentally measured through eCLIP and PAR-CLIP protocols, enabling the quantification of locally accumulated reads, and the calling of peaks. Such peaks were obtained for 150 RBPs from eCLIP data (86) , and for 59 RBPs from PAR-CLIP data (61). (Middle panel) Sequences from these peaks were used to train two deep learning models, composed of convolutional neural networks enabling the detection of complex sequence motifs. These models can then be applied to predict for a given sequence its potential for binding by a RBP. The pysster models are trained separately for each RBP, while DeepRIPE is trained in a multi-task fashion and simultaneously for all input RBPs. (Right panel) A selection of high-performance models was established through evaluation of performance of the models, from overall performance metrics to in-practice, sequence-wide evaluation. b. All retained models were applied to scan the entire genome of SARS-CoV-2, and binding sites were predicted from consecutive, high-prediction scores positions. Sequence motifs underlying RBP binding sites were also identified by interrogating both CNNs via Integrated Gradients. Predictions were compiled in the first in silico map of host-protein -viral RNA interactome for SARS-CoV-2. c The prediction models were applied to evaluate the impact of variants of concerns, d as well as to evaluate the evolutionary trajectory of affinity of host RBPs to other coronaviruses' genomes. (a) CNBP LARP1 (f) Figure 2 : Evaluation of pysster models' performance and high-quality model selection. a. Receiver Operating Curve (ROC) and Precision Recall Curve (PRC) for all 150 pysster models trained from ENCODE eCLIP datasets. A first threshold of 0.6 was set on the area under the PRCs (auPRC), leading to a subset of 79 models passing the threshold. b. Boxplots of correlations between eCLIP and prediction scores from 100 left-out transcripts per RBP model. This correlation highlights the performance of models in a realistic context of full-sequence-length scan. A second threshold was thus set on the median correlation coefficient, leading to a subset of 93 models passing the threshold. The 10 models with highest median correlation are displayed in a detailed sub-plot. c. Genome-browser view illustrating the comparison between eCLIP signals and model prediction scores over full-length transcripts. Two of the best models are presented, with signal from left-out transcripts with high correlation between eCLIP log-fold-change signals and prediction scores from the pysster models. d. Scatterplot of the AUPRC and median correlation values for each model, highlighting the final subset of high-quality models. The top 10 models are labeled. e. Comparison of genome-wide eCLIP signal and pysster prediction scores from the CNBP eCLIP datasets generated over the SARS-CoV-2 genome by (69). f. Boxplot of pysster prediction scores from position within or without overlap from called narrow peaks, for the CNBP model and the LARP1 model. a Single-nucleotide probability score for RBFOX2 (left) and TARDBP (right) RBP binding as computed by the corresponding pysster models across the whole SARS-CoV-2 genome. The higher the score, the higher the likelihood of a binding event at that position. Points highlighted in strong color correspond to significant predictions, i.e. with bound probability significantly higher than random (empirical p-value < 0.01, see Methods). Wider binding sites, encompassing more than one significant position are shown as vertical bars underneath each prediction profile, together with their corresponding binding motifs as extracted by means of attribution maps (see Methods). b Single-nucleotide probability score for MBNL1 (left) and QKI (right) RBP binding as computed by the corresponding DeepRiPe models. Significant positions (empirical p-value < 0.01) are highlighted in strong color, and computed binding sites together with their corresponding motifs are shown underneath. Figure 4 : Impact of variants from SARS-CoV-2 strains on predicted binding sites. a. Joint heatmap of delta scores from the 290 identified variants in the different SARS-CoV-2 strains. Delta-scores represent the difference in prediction score of a prediction model between alternative and reference sequences centered on each variant. Only the 315 impacts labeled as change-of-binding are colored (see 3.11). Delta score color scale is capped so as to show low delta score impacts. RBPs and mutations without any such impact across strains are dropped from the heatmap. b. Complete heatmap of delta scores from 31 variants associated to the alpha viral variant. The top 10 with highest absolute delta scores are lined out, with yellow color indicating the ones labeled as change-of-binding. Some sites are further investigated through integrated gradients, comparing the sequence motifs identified by the prediction models against known motifs from mCrossBase (16). c. Complete heatmap of delta scores from 16 variants associated to the delta viral variant. d,e. Results from the in silico mutagenesis over the SARS-CoV-2 genome. Nucleotides across the viral genome were perturbed towards the three alternative bases, generating a reference distribution of possible delta-scores, notably highlighting positions with highest impacts. Here, d) and e) display the position-wise reference score (top) and delta score (bottom) for PUM2 and FTO, respectively. (f) (g) Figure 5 : Comparison of SARS-CoV-2 and 6 other human coronaviruses. a,b,c. Binding sites were predicted over the seven human coronaviruses, and their number counted over the entire genome (a) or over the 3' (b) and 5' (c) UTRs. Hierarchical clustering was applied to evaluate the proximity between viruses in terms of binding sites composition. d,e,f,g. Examples of evolutionary conserved, gained, and lost binding sites between the three high-severity viruses MERS, SARS-CoV-1, and SARS-CoV2. Panel d shows an example for FTO binding sites found only in SARS-Cov-2 and SARS-CoV-1 in their 3' UTRs. Panel e shows a binding site for FXR2 only shared between MERS and SARS-CoV-1 in their 3' UTR. Panel f shows a binding site for TARDBP exclusive to SARS-CoV-2 in the 5' UTR. Panel g shows a binding site for FXR2 only shared between SARS-CoV-2 and SARS-CoV-1 in the 5' UTR. Significance Cutoff n/a stringent lax ZNF800 AGGF1 RBM22 KHSRP CSTF2 FMR1 TARDBP TIAL1 EWSR1 U2AF2 PTBP1 QKI SAFB2 DDX3X IGF2BP2 NONO FAM120A HNRNPA1 HNRNPC HNRNPK ILF3 IGF2BP1 IGF2BP3 KHDRBS1 AKAP8L CAPRIN1 HNRNPM SND1 CPSF7 DND1 SRRM4 ELAVL2 ELAVL3 SF3A3 ELAVL4 CSTF2T NCBP2 ZC3H7B FTO RBM20 NOP58 ZRANB2 ZFP36 EIF4G2 AATF AGO3 CPSF6 FUBP3 GPKOW CPSF1 FIP1L1 AGO1 DDX59 AQR GRSF1 HNRNPD HNRNPL SRSF7 AGO2 ELAVL1 PUM2 XRN2 PRPF8 TAF15 PCBP2 SRSF1 TRA2A MATR3 SRSF9 PCBP1 RPS3 Q9UN81 SF3B4 RBFOX2 SUGP2 FXR2 RBPMS MBNL1 FXR1 YBX3 FKBP4 G3BP1 DKC1 GTF2F1 NOP56 ZNF800 AGGF1 RBM22 KHSRP CSTF2 FMR1 TARDBP TIAL1 EWSR1 U2AF2 PTBP1 QKI SAFB2 DDX3X IGF2BP2 NONO FAM120A HNRNPA1 HNRNPC HNRNPK ILF3 IGF2BP1 IGF2BP3 KHDRBS1 AKAP8L CAPRIN1 HNRNPM SND1 (7). RBPs from different methods color coded above the heatmap: pysster-exclusive in red, DeepRiPe-exclusive in blue, and shared between models in grey. The epigenetic implication in A large-scale binding and functional map of human rna-binding proteins Structural analysis of sars-cov-2 genome and predictions of the human interactome Identification of rna-protein interaction networks 1008 involved in the norovirus life cycle RNA-protein interaction analysis of 1010 SARS-CoV-2 5' and 3' untranslated regions reveals a role of lysosome-associated membrane protein-2a during viral 1011 infection. mSystems Coronavirus biology and replication: 1013 implications for sars-cov-2 Genetic screens identify host factors for 1017 SARS-CoV-2 and common cold coronaviruses Genome-wide crispr screens reveal host factors critical for 1020 sars-cov-2 infection Advances and challenges in the detection of 1022 transcriptome-wide protein-rna interactions Nucleocapsid phosphorylation and rna helicase ddx1 recruitment 1024 enables coronavirus transition from discontinuous to continuous transcription The trans-omics landscape of 1031 COVID-19 Discovery and Functional Interrogation of the Virus and Host RNA Interactome of SARS-Cov-2 Proteins Regulation of m6a methylation as a new therapeutic option against covid-19 Membrane 1041 fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant RBP classification Vandelli A (2020) -catRAPID Sun L (2021) -PrismNet Flynn RA (2021) -Huh7.5, 24h, ChIRP-MS Flynn RA (2021) -Huh7.5, 48h, ChIRP-MS Flynn RA (2021) -VeroE6, 24h, ChIRP-MS Flynn RA (2021) -VeroE6 HEK293T, 5'UTR, RaPID assay Gordon DE (2020) -HEK293T A549 HCoV-NL63 Caco−2, differential proteome Caco−2, differential proteome Caco−2, differential proteome Caco−2, differential proteome Huh7, differential proteome African Green Monkey VeroE6, (V1) SARS-CoV-2 African Green Monkey VeroE6, (V2) SARS-CoV-2 African Green Monkey VeroE6, MERS African Green Monkey VeroE6, MERS-CoV T1015N African Green Monkey VeroE6, HKU5-SARS-CoV-1-Spike Wang R (2020) -Huh-7.5, HCoV-229E HCoV-OC43 African G. Monkey VeroE6, VSV-Spike Hospitalized vs. Non−hospitalized Population vs.Hospitalized Population vs. Very severe n=128, leukocytes, transcriptomics COVID-19 * ICU Overmyer KA (2020) -n=128, leukocyte transcriptomics n=128, plasma, proteomics Supplementary Figure 2: Impact of variants of concern on predicted binding sites. a. Accumulation of high-impact variants of concern in viral components for each lineage. The subset of high-impact variants here corresponds to the one represented in Figure 4a, i.e. the top 20% of binding-impacting variants. b. Accumulation of impacted RBP sites for each lineage Authors F.B. and N.S.M. hold positions at knowing01 GmbH that might benefit or be at a disadvantage from the 1073 published findings. The remaining authors declare no conflict of interest that is relevant to the content of this article.